Tivdak (tisotumab vedotin-tftv) vs Orserdu (elacestrant)

Tivdak (tisotumab vedotin-tftv) is an antibody-drug conjugate specifically approved for the treatment of recurrent or metastatic cervical cancer that is not amenable to curative treatment with surgery and/or radiation, and it works by targeting tissue factor on cancer cells to deliver a cytotoxic agent. Orserdu (elacestrant), on the other hand, is a selective estrogen receptor degrader (SERD) indicated for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in postmenopausal women or adult men. When deciding between these two medications, one should consider the type of cancer they are diagnosed with, as Tivdak is specific to cervical cancer, while Orserdu is tailored for certain types of breast cancer, and consultation with a healthcare provider is essential to determine the appropriate treatment based on individual health status and cancer characteristics.

Difference between Tivdak and Orserdu

Metric	Tivdak (tisotumab vedotin-tftv)	Orserdu (elacestrant)
Generic name	Tisotumab vedotin-tftv	Elacestrant
Indications	For the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.	For the treatment of postmenopausal women or adult men with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer with a specific ESR1 mutation.
Mechanism of action	Antibody-drug conjugate targeting tissue factor, delivering a cytotoxic agent directly to tumor cells.	Oral selective estrogen receptor degrader (SERD) which competitively binds to estrogen receptors and degrades them, reducing the effects of estrogen on the growth of breast cancer cells.
Brand names	Tivdak	Orserdu
Administrative route	Intravenous infusion	Oral
Side effects	Fatigue, nausea, alopecia, constipation, decreased appetite, and others.	Nausea, vomiting, fatigue, increased cholesterol levels, and others.
Contraindications	Hypersensitivity to tisotumab vedotin-tftv or any of its components.	Hypersensitivity to elacestrant or any of its components.
Drug class	Antibody-drug conjugate	Selective estrogen receptor degrader (SERD)
Manufacturer	Seagen Inc. and Genmab	Radiant Pharmaceuticals

Efficacy

Efficacy of Tivdak (tisotumab vedotin-tftv) in Gynecological Cancer

Tivdak (tisotumab vedotin-tftv) is a novel medication specifically indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tivdak is an antibody-drug conjugate that targets tissue factor, which is commonly overexpressed in cervical cancer. The efficacy of Tivdak was evaluated in a pivotal clinical trial, innovaTV 204, which was a single-arm, multicenter study. The results showed a meaningful clinical benefit, with an objective response rate (ORR) of 24% in patients treated with Tivdak. This included a complete response rate of 7% and a partial response rate of 17%. The median duration of response (DOR) was observed to be 8.3 months, indicating a potential for prolonged benefit in some patients.

Efficacy of Orserdu (elacestrant) in Gynecological Cancer

Orserdu (elacestrant) is not directly indicated for the treatment of gynecological cancers. It is an investigational oral selective estrogen receptor degrader (SERD) that is being studied for its efficacy in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. As of the knowledge cutoff date, there is limited data on the efficacy of Orserdu in gynecological cancers, and its use in this context would be considered off-label. Clinical trials and further research would be necessary to establish its efficacy and safety profile for the treatment of gynecological malignancies.

In conclusion, Tivdak has demonstrated efficacy in the treatment of recurrent or metastatic cervical cancer, offering hope for patients who have progressed on or after chemotherapy. On the other hand, Orserdu's efficacy in gynecological cancers remains to be determined through clinical trials and research. Patients and healthcare providers should consider the current indications and available evidence when considering these medications for the treatment of gynecological cancers.

It is important for patients to consult with their healthcare provider to understand the potential benefits and risks of these treatments and to determine the most appropriate therapeutic strategy based on their individual clinical circumstances. As with all medications, the use of Tivdak and Orserdu should be guided by clinical evidence and in accordance with regulatory approvals.

Regulatory Agency Approvals

Tivdak

Food and Drug Administration (FDA), USA

Orserdu

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Tivdak or Orserdu today

If Tivdak or Orserdu are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Tivdak

Buy Orserdu

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: